Harrington, K JKazi, RBhide, S ANewbold, KNutting, C M2013-01-152013-01-152010-07Harrington K J, Kazi R, Bhide S A, Newbold K, Nutting C M. Novel therapeutic approaches to squamous cell carcinoma of the head and neck using biologically targeted agents. Indian Journal of Cancer. 2010 Jul-Sept; 47(3): 248-259.http://imsear.searo.who.int/handle/123456789/144347Despite significant improvements in the treatment and outcomes of patients with squamous cell carcinoma of the head and neck (SCCHN) that have resulted from technological advances in radiation delivery and the use of cytotoxic chemotherapy, there is still a pressing need for novel therapies. In the last two decades, our understanding of the molecular biological basis of cancer has provided us with a new framework for developing specific targeted therapies. It is likely that the next wave of developments will include active small molecule inhibitors of epidermal growth factor receptor (EGFR) (and other members of the c-erbB family of receptors), antiangiogenic agents, and drugs that can increase proapoptotic signaling in cancer cells. As with cetuximab, it is most likely that these new agents will first find a niche in the context of combination regimens with standard anticancer therapeutics.enBiologically targeted agentsepidermal growth factor receptorEGFR inhibitorstyrosine kinase inhibitorsAngiogenesis Inhibitors --therapeutic useAntibodies, Monoclonal --pharmacologyAntibodies, Monoclonal --therapeutic useAntineoplastic Combined Chemotherapy Protocols --therapeutic useApoptosis --drug effectsBiological Therapy --trendsCarcinoma, Squamous Cell --drug therapyCarcinoma, Squamous Cell --metabolismCarcinoma, Squamous Cell --pathologyChemotherapy, AdjuvantDrug DiscoveryHead and Neck Neoplasmsdrug therapyHead and Neck Neoplasms --metabolismHead and Neck Neoplasms --pathologyHumansIntracellular Signaling Peptides and Proteins --agonistsReceptor, Epidermal Growth Factor --antagonists & inhibitorsArticle